转移性激素敏感性前列腺癌的前列腺局部放疗:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入3项3期随机对照试验(HORRAD、STAMPEDE、PEACE-1),评估在系统治疗基础上加用局部放疗对转移性激素敏感性前列腺癌患者总生存的影响,发现局部放疗未显著改善全部患者或低转移负荷患者的总生存,但显著改善雄激素剥夺抵抗无生存期并减少局部事件。
要点
- 局部放疗未显著改善全部mHSPC患者的总生存(HR=0.92,95%CI 0.85-1.00,p=0.06)。
- 低转移负荷患者的总生存亦无显著改善(HR=0.74,95%CI 0.51-1.06,p=0.1)。
- 探索性分析显示局部放疗显著改善雄激素剥夺抵抗无生存期(HR=0.76,95%CI 0.70-0.82,p<0.001)。
核心结论
- 在未选择的接受现代系统治疗的mHSPC患者中,局部放疗未改善总生存。
- 局部放疗可延迟ADT抵抗并减少局部不良事件,毒性相对可耐受。
研究设计与样本
- 前瞻性注册的系统评价与荟萃分析(CRD42025648251),检索MEDLINE、Scopus、CENTRAL和Google Scholar(2025年3月)。
- 纳入评估在系统治疗基础上加用放疗以改善mHSPC患者OS的3期随机对照试验。
- 共纳入3项RCT:HORRAD(n=432)、STAMPEDE(n=2,061)、PEACE-1(n=1,173)。
- 系统治疗方案:HORRAD为ADT,STAMPEDE为ADT±多西他赛,PEACE-1为ADT±多西他赛±阿比特龙。
- 采用随机效应模型合并风险比(HR),使用Cochrane RoB 2工具评估偏倚风险。
主要发现
- 局部放疗与全部患者OS无显著改善相关(HR=0.92;95%CI 0.85-1.00;p=0.06)。
- 低转移负荷患者OS无显著改善(HR=0.74;95%CI 0.51-1.06;p=0.1)。
- 探索性分析显示雄激素剥夺抵抗无生存期显著改善(HR=0.76;95%CI 0.70-0.82;p<0.001)。
- HORRAD试验中局部前列腺癌相关事件:局部放疗组18% vs 对照组30%。
- PEACE-1试验中局部前列腺癌相关事件:局部放疗组12% vs 对照组22%;STAMPEDE试验为49% vs 51%,无显著差异。
临床怎么用
- 局部放疗不应常规用于所有mHSPC患者以改善总生存。
- 可考虑局部放疗以延迟ADT抵抗和减少局部前列腺癌相关事件。
- 未来需细化选择标准,理想情况下使用PSMA-PET成像、动态反应标志物和/或基因组分析来识别最可能受益的患者。
局限性
- 局部放疗对低转移负荷患者OS的改善未达统计学显著性(p=0.1)。
- 局部事件减少在STAMPEDE试验中未观察到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The incidence of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) is rising with the increasing use of next-generation imaging. Local radiotherapy (RT) was shown to improve survival in patients with mHSPC; however, new data require a re-assessment of the indication and value of local RT in mHSPC. METHODS: In this prospectively registered systematic review and meta-analysis (CRD42025648251), we searched MEDLINE, Scopus, CENTRAL, and Google Scholar in March 2025 for phase 3 RCTs evaluating the addition of RT to systemic therapy to improve OS in mHSPC patients. Hazard ratios (HRs) were pooled using random-effects meta-analysis. Risk of Bias was assessed with Cochrane's RoB 2 tool. RESULTS: Out of the 10,615 individual records, we identified three RCTs: HORRAD (n = 432), STAMPEDE (n = 2,061), and PEACE-1 (n = 1,173). The systemic treatment included androgen deprivation therapy (ADT) in HORRAD, ADT ± Docetaxel in STAMPEDE, and ADT ± Docetaxel ± Abiraterone in PEACE-1 trial. Local RT was not associated with significantly improved OS in all patients (HR = 0.92; 95 % confidence interval [CI] 0.85-1.00; p = 0.06), or in those with low metastatic burden (HR = 0.74; 95 %CI 0.51-1.06; p = 0.1); however, exploratory analyses showed a significant improvement in androgen deprivation resistance-free survival (HR = 0.76; 95 %CI 0.70-0.82; p < 0.001). Local RT was associated with significant reduction in local prostate cancer related events in the HORRAD (18 % vs. 30 %) and PEACE-1 (12 % vs. 22 %) trials, but not in the STAMPEDE trial (49 % vs. 51 %). CONCLUSION: Local RT does not improve OS in unselected patients treated with modern systemic therapies for mHSPC. However, it delays ADT resistance and reduces local adverse events, with relatively tolerable toxicity. Future studies should refine selection criteria, ideally using PSMA-PET imaging, dynamic response markers, and/or genomic profiling, to identify mHSPC patients most likely to benefit from local RT.
引用
- Roessler N, Miszczyk M, Dematteis A, et al. Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. Clin Transl Radiat Oncol. 2025. PMID: 40687731. doi:10.1016/j.ctro.2025.101009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。